Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
6/1/2026, 12:00:00 AM
Announced on June 1, 2026, that the Phase 3 LITESPARK-012 study of a Keytruda-based triplet therapy in first-line advanced clear cell renal cell carcinoma (RCC) did not meet its primary endpoints.
Korean Translation
2026년 6월 1일 진행성 투명세포 신세포암(RCC) 1차 치료를 위한 키트루다 기반 3중 병용 요법의 임상 3상 LITESPARK-012 연구가 1차 평가변수를 충족하지 못했다고 발표함.
Related Recent Events
Conocophillips (COP) · Earnings Release
As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.
8/6/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q2 2026 earnings release is scheduled. This event is estimated to have a price impact of at least 1%.
8/6/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
MetLife is scheduled to release its Q2 2026 earnings results on August 5, 2026; a medium impact is expected as quarterly results are key performance indicators, scheduled.
8/5/2026, 12:00:00 AM
Cabot Corp (CBT) · Earnings Release
Q3 2026 earnings release scheduled. Analysts forecast an EPS of approximately $1.63 to $1.66 forecasted. Low importance estimated: historical price reaction to earnings is typically 1-5%.
8/3/2026, 12:00:00 AM
The Cigna Group (CI) · Earnings Release
Second quarter 2026 financial results are scheduled to be released. This recurring financial event is estimated to have a medium price impact of at least 5% based on historical volatility scheduled.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM